Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
Summary of Consolidated Financial Results
(For the First Quarter ended June 30, 2023) [Under Japanese GAAP]
August 2, 2023 Tokyo Stock Exchange
Company name: KYORIN Pharmaceutical Co., Ltd.
Code number: 4569
Web site: https://www.kyorin-pharm.co.jp/
Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer
Contact: Sakurou Banba, Director, Finance & Accounting TEL (03) 3525-4701
Scheduled date for submitting securities report: August 9, 2023
Scheduled date for starting dividend payment: -
(Amounts rounded down to the nearest million yen)
1. Consolidated results for the three months ended June 30, 2023 (from April 1, 2023 to June 30, 2023)
Consolidated operating results
(Percentage changes relative to previous corresponding period)
Net sales
Operating profit
Ordinary profit
Profit attributable to
owners of parent
Three months ended
Million yen
%
Million yen
%
Million yen
%
Million yen
%
June 30, 2023
27,854
13.1
710
45.1
913
17.2
676
-42.8
June 30, 2022
24,619
-0.3
489
-
779
-
1,183
-
(Note) Comprehensive income: For the three months ended June 30, 2023: 1,152 million yen (-51.3%),
For the three months ended June 30, 2022: 2,367 million yen (- %)
Earnings per share (Basic)
Earnings per share (Diluted)
Three months ended
Yen
Yen
June 30, 2023
11.81
-
June 30, 2022
20.65
-
(2) Consolidated financial position
Total assets
Net assets
Equity ratio
As of
Million yen
Million yen
%
June 30, 2023
172,542
124,753
72.3
March 31, 2023
176,045
125,461
71.3
(Note) Equity: For the three months ended June 30, 2023: 124,753 million yen,
For the fiscal year ended March 31, 2023: 125,461 million yen
2. Dividends
Annual dividends per share
(Record date)
First quarter-end
Second quarter-end
Third quarter-end
Fiscal year-end
Total
Yen
Yen
Yen
Yen
Yen
Fiscal year ended
-
20.00
-
32.00
52.00
March 31, 2023
Fiscal year ended
-
March 31, 2024
Fiscal year ending
March 31, 2024
20.00
-
32.00
52.00
(Forecast)
(Note) Revisions to the dividend forecast in the current quarter: None
3. Forecast of consolidated for the year ending March 31, 2024 (from April 1, 2023 to March 31, 2024)
(Percentage changes relative to previous corresponding period)
Net sales
Operating profit
Ordinary profit
Profit attributable to
Earnings
owners of parent
per share
Million yen
%
Million yen
%
Million yen
%
Million yen
%
Yen
First half
53,700
9.4
600
-22.9
900
-23.2
700
-43.7
12.22
Full year
2.6
6,000
3.7
116,200
17.1
6,500
11.5
4,900
85.51
(Note) Revisions to the dividend forecast in the current quarter: None
1
4. Other
Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): Yes
Newly included: None
Excluded:
1 company (The former Kyorin Pharmaceutical Co. Ltd.)
Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes
Changes in accounting policies, changes in accounting estimates and restatements
Changes in accounting policies due to revisions to accounting standards and other regulations: None
(ii) Changes in accounting policies due to other than (i)
: None
(iii) Changes in accounting estimates
: Yes
(iv) Restatements
: None
(4) Number of shares issued (common stock)
(i) Number of issued shares at the end of the period (including treasury shares)
As of June 30, 2023: 64,607,936 shares,
Fiscal year ended March 31 2023: 64,607,936 shares
(ii) Number of treasury shares at the end of the period
As of June 30, 2023: 7,304,078 shares,
Fiscal year ended March 31 2023: 7,304,066 shares
Averaged number of shares of during the period As of June 30, 2023: 57,303,858 shares,
As of June 30, 2022: 57,301,882 shares
This quarterly financial report is not subject to audit procedures by Certified Public Accountants or audit firm.
Explanations about the appropriate use of the business forecasts and other noteworthy points.
These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.
(Methods for obtaining supplementary materials and content of financial results disclosure)
Supplementary materials will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
Kyorin Pharmaceutical Co. Ltd. published this content on 02 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2023 07:16:10 UTC.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.